Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opsens Inc T.OPS

OpSens Inc. is a medical device cardiology-focused company. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. The Company’s segments include Medical and Industrial. The Medical segment focuses on physiological measurements, such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR) in the coronary artery disease market and also supplies a range of miniature optical sensors to measure pressure and temperature to be used in a range of applications that can be integrated into other medical devices. The Industrial segment develops, manufactures and installs fiber optic sensing solutions for critical and demanding industrial applications. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and lesions access. It is approved for sale in the United States, European Union, Japan and Canada.


TSX:OPS - Post by User

Bullboard Posts
Post by PChung888on Apr 19, 2017 9:48am
195 Views
Post# 26136465

Earnings

Earnings

Opsens Reports Q2 2017 Results - Quarterly Consolidated Revenues Up 75% to $4.8 Million

 

QUEBEC CITY, April 19, 2017 /CNW Telbec/ - Opsens Inc. ( OPSSF

Loading... Loading...
) ("Opsens" or the "Company") (OTCQX: OPSSF) today reported its results for the second quarter ended February 28, 2017.

 

HIGHLIGHTS

  • Growth in sales of products to measure Fractional Flow Reserve ("FFR") in Q2 2017 at $3,117,000 compared with $1,252,000 in Q2 2016, an increase of $1,865,000 or 149%;
  • Growth in FFR revenues in first half of 2017 at $5,860,000 compared with $2,145,000 for the same period in 2016, an increase of $3,715,000 or 173%;
  • Growth in consolidated revenues for Q2 2017 at $4,808,000 compared with $2,741,000 for Q2 2016, an increase of $2,067,000 or 75%;
  • Closing of a $15 million equity financing;
  • Opsens ( OPSSF
    Loading... Loading...
    ) graduates to the Toronto Stock Exchange ("TSX"), Canada's largest stock market.

IMPLEMENTATION OF THE GROWTH STRATEGY

Opsens' ( OPSSF

Loading... Loading...
) commercial networks continue to demonstrate success from quarter to quarter. FFR revenues for the first half of 2017 are already higher than FFR revenues recorded for the entire previous year. "We are confident that the OptoWire's distinctive features, which are widely recognized by key opinion leaders in interventional cardiology, will allow us to capitalize on the fast-growing FFR market," said Louis Laflamme, Opsens' ( {C} OPSSF
) President and Chief Executive Officer.

 

"The improvement in our production processes over the past few months has allowed us to increase our competitiveness and our ability to meet the growing demand for our products. Opsens' ( {C} OPSSF

Loading... Loading...
) cash position now stands at approximately $16 million, giving the Company the flexibility to execute its commercialization plan worldwide, including the expansion of marketing of our FFR products," added Laflamme.

 

FINANCIAL RESULTS FOR THE THREE-MONTH PERIOD ENDED FEBRUARY 28, 2017 - SALES GROWTH

In the second quarter, consolidated sales increased by 75%, supported by FFR sales growth. This increase was partially offset by lower revenues of $582,000 in the industrial sector.

Gross margin increased to $2,254,000 for the quarter ended February 28, 2017 compared with $767,000 for the same period last year.

Net loss decreased to 1,001,000 for the three-month period ended February 28, 2017 compared with a net loss of $1,523,000 for the corresponding period last year.

During the quarter, licensing revenues of $1,007,750 (US$750,000) related to a technical milestone payment received were recorded.


Bullboard Posts